Urea, N-[2-[6,7-dihydro-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl]ethyl]- Property

Density 

1.29±0.1 g/cm3(Predicted)

storage temp. 

-10 to -25°C

solubility 

DMSO: 2mg/mL, clear (Warmed)

pka

13.73±0.46(Predicted)

form 

powder

color 

white to beige

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H335May cause respiratory irritation

H361Suspected of damaging fertility or the unborn child

H373May cause damage to organs through prolonged or repeated exposure

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P281Use personal protective equipment as required.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P308+P313IF exposed or concerned: Get medical advice/attention.

P314Get medical advice/attention if you feel unwell.

P321Specific treatment (see … on this label).

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P362Take off contaminated clothing and wash before reuse.

P405Store locked up.

P501Dispose of contents/container to..…

Urea, N-[2-[6,7-dihydro-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl]ethyl]- Chemical Properties,Usage,Production

Uses

RPL 554 is a known drug candidate for respiratory diseases, particularly in patients with asthma or chronic obstructive pulmonary diseases.

Biological Activity

RPL554 (Ensifentrine) is a long acting, potent and specific dual inhibitor of PDE 3/4 (phosphodiesterase 3 and 4). RPL554 displays a broad range of both bronchoprotective and anti-inflammatory activities. Also, RPL554 synergizes with anti-muscarinic drugs in inhibition of ASM tone. RPL554 (Ensifentrine) exhibits anti-inflammatory effects through reduced production of the monocyte chemoattractant protein-1 (MCP-1) and granulocyte monocyte colony stimulating factor (GM-CSF) in cystic fibrosis bronchial epithelial cells during challenge with Interleukin-1β.